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Prolactinomas are the commonest pituitary adenomas and the major pathological cause of hyperprolactinaemia. Symptomatic
prolactinomas are treated mainly by dopamine agonists; surgery and radiotherapy are options for nonresponders. Schizophrenia
treatment is based on antipsychotics, which acts mainly at serotonergic and dopaminergic systems. We report a case of a 39-
year-old schizophrenic male patient that was diagnosed with a macroprolactinoma 8 years after his ﬁrst psychotic episode. The
association of Schizophrenia and prolactinoma represents a clinical challenge once the treatment of one disease can exacerbate the
symptoms of the other.
1.Introduction
Prolactinomas are adenomas originated from pituitary lac-
totrophs and represent about 40% of all pituitary adenomas
[1]. The diagnosis is established by elevated serum pro-
lactin levels (>100ng/mL) and MRI imaging [1, 2]. The
prolactin release is tonically inhibited by dopamine and
the main clinical approach to the treatment of prolactino-
mas is the use of dopamine agonists, such as cabergoline
and bromocriptine, which activate D2-receptors on the
lactotrophs, thus promoting the reduction of tumor size
[1, 2]. On the other hand, several pieces of evidence
suggest that positive symptoms of schizophrenia result from
a hyperactivation of dopamine transmission subcortically
and the use of medications that act, among other neuro-
transmissions systems, at the dopamine system antagonists
are the basis of its treatment [3–6]. The management of
patients with both disorders is quite challenging, since the
strategies of treatment confront opposing mechanisms of
action.
2.CaseDescription
A 39-year-old single man was referred to the Psychiatric
Department of UNIFESP by the Neuroendocrinology unit.
At the age of 29, he started presenting self-reference and
persecutory delusions (poisoned food, people following or
accusing him), abnormal anxiety and fear of something
happening to him, auditory hallucinations (familiar people
asking him for help), and important impairment in social
and professional performances, all of which persisted for at
least 5 weeks. He was diagnosed with schizophrenia and was
prescribed haloperidol 5mg per day and biperiden 2mg per
day. Full remission was reached within a few days; however,
everytimethedosageswerereduced,thesymptomsrecurred.
He used both medications regularly for over 8 years and had
mild impairment in global functioning.
At the age of 37, he presented sudden bitemporal hemi-
anopia, worse at the right side, which progressed to complete
amaurosis within a month. There were no sexual complaints.
Serum prolactin level was 3616ng/mL. TSH and routine2 Case Reports in Medicine
biochemical analysis were normal. An MRI scan was per-
formed and a 25×20×12mm pituitary macroadenoma was
diagnosed. After psychiatric medication was discontinued,
the patient underwent surgical intervention. The histological
exam conﬁrmed the hypothesis of macroprolactinoma. At
the postoperative period, quetiapine 25mg per day and
bromocriptine 2.5mg per day were prescribed. Quetiapine
was progressively increased to 200mg per day and later to
400mg per day. The option for low quetiapine doses was
made in order to cautiously observe serum prolactin levels.
Prolactinaemia reduced to 286,7ng/mL twenty days after the
procedure.
After 6 months, serum prolactin level was 121ng/mL
and bromocriptine dosage was increased to 5mg per day.
Psychotic symptoms worsening leads to inpatient psychiatric
admission. The bromocriptine dose was decreased to 1mg
per day and the quetiapine dose was increased to 600mg
per day. Stabilization in mental status was reached after
four weeks. Control MRI revealed residual tumor tissue and
radiotherapy was programmed with no modiﬁcations in
the prescription. Patient underwent 27 radiotherapy sessions
with a total dosage of 4860 cGy with no procedure-related
complications.Aftertenmonths,thecurrentserumprolactin
level is 56.3ng/mL and no positive psychotic symptoms
were presented during this period. Additionally, the patient
currently lives alone and does his own housekeeping. He
complains of impaired initiative and lack of social interest.
3. Discussion
Hyperprolactinaemia usually causes oligo/amenorrhoea,
galactorrhoea, and infertility in premenopausal women, and
impotence, infertility, and decreased libido in men [1, 3].
Larger tumors cause compression of local structures, thus
leading to hypopituitarism or neurological manifestations
[1–3]. The presence of neurological symptoms, including
headaches and visual impairment, ranging from quad-
rantanopia to bitemporal hemianopia or scotomas, are
indicators of the existence of space-occupying intracranial
neoplasm [1, 3–5].
Schizophrenic patients may have increased serum pro-
lactin levels particularly due to the use of antipsychotic
medication. However, serum levels superior to 100ng/mL
in women and 50ng/ml in men, especially with concurrent
symptoms, should be investigated [1, 3, 4]. In these cases,
physiological (specially pregnancy) and pharmacological
causes (tricyclic antidepressants, verapamil) must be ruled
out ﬁrst through careful clinical history [1, 3]. A complete
clinical evaluation is essential, including physical examina-
tion,routinebiochemicalanalysis(liverandrenalfunctions),
pregnancy test, and TSH serum level [1, 3]. If the patient is
taking a drug known to cause hyperprolactinaemia, the drug
should be withdrawn for at least 72h, if possible [1]. An MRI
ofthesellaturcicaisindicatedinthepresenceofneurological
symptoms [1, 3].
Prolactinomas are the most common pathological cause
of hyperprolactinaemia and are generally classiﬁed as micro-
prolactinomas (no larger than 10mm in diameter) or
macroprolactinomas (larger than 10mm in diameter) [1–3].
Although being almost invariably benign, occasionally they
can be locally aggressive and compress contiguous structures
[1–3]. The combination of hyperprolactinaemia and MRI
suggestive imaging is not unequivocally diagnostic; only
histopathological study is. Since the minority of the prolacti-
nomas is removable, the strategy is to initiate dopaminergic
agonist medication and consider the reduction in tumor size
as conﬁrmatory. Surgery should be a viable option if there
is a good probability of removal of the entire tumor [1, 3].
Radiotherapy is reserved to refractory tumors and to cases of
intolerance to dopaminergic agonists [1, 3].
A search at PubMed database was performed and we
identiﬁed seven reported cases of prolactinoma diagnosed
after the onset of a psychotic disorder [4, 5]. The use
of both dopamine agonists and antagonists was inevitable
and necessary to achieve clinical stability in ﬁve of them.
Surgery was successful in two cases. A ﬁrst generation
antipsychotic accounted for psychiatric stabilization of four
of these patients and quetiapine was successfully used in one
case [4, 5].
Pal and Sarino (2000) reported a case in which a
12mm-diameter prolactinoma was identiﬁed in a woman
during a psychiatric hospitalization originally caused by
acute psychotic symptoms [7]. Despite the regular daily use
of 4mg of oral risperidone and 15mg of bromocriptine,
the tumor increased and visual impairment became worse.
After antipsychotic treatment was changed and olanzapine
5mg per day was initiated, both psychotic and endocrine
symptoms decreased [7].
Akkaya et al. (2009) reported three cases of patients diag-
nosedwithschizophrenia[8].Markedelevationsinprolactin
serum levels were identiﬁed in these patients after two weeks
of use of amisulpride. Further MRI investigation revealed
microprolactinomas (2 to 5mm diameter) in all cases [8].
No prolactinoma-related intervention was performed [8].
Data from positron emission tomography (PET) studies
evaluating D2 occupancy by antipsychotics indicate that
thresholds of 65%, 72%, and 78% are associated with
clinical eﬃcacy, hyperprolactinaemia, and extrapyramidal
symptoms, respectively [9]. First generation antipsychotics
usually have higher D2 occupancy rates and have a greater
aﬃnity for tuberoinfundibular pathway [3], thus promoting
higher increases in prolactin secretion [3–8].
Diﬀerently, second generation antipsychotics are a more
heterogeneous group regarding actions on diﬀerent neuro-
transmitters systems. Clozapine at doses of 125 to 600mg
has a D2 occupancy of 20% to 67%, below the threshold
predictive of hyperprolactinaemia [9], which is consistent
with the less pronounced hyperprolactinemia related to the
drug[4,9].Thus,clozapineshouldbeexpectedtohavelower
eﬀect on growth of a PRL-producing tumor. Risperidone
and paliperidone are associated with persistently increased
prolactinserumlevels,evengreaterthanotherantipsychotics
[9] and, thus, should never be used in patients with prolacti-
nomas. Olanzapine and ziprasidone are probably associated
with mild-to-minimal transient elevations in prolactin levels
[9]. Aripiprazol appears not to elevate prolactin levels and
there are evidences that it can actually lower PRL levels at
higher doses because it is a partial DA agonist [9, 10].Case Reports in Medicine 3
Quetiapine is also a second-generation antipsychotic,
similar in structure to clozapine [9–11]. Clinical data
indicates that quetiapine is not associated with elevations
in prolactin levels [9–11]. It has been suggested that
quetiapine transiently occupies D2 receptors, which allows
modest occupancy of D2 receptors (0–27%) that rapidly
declines to minimal levels 12 to 24 hours after the last
dose [9]. Quetiapine has an overall favorable adverse eﬀects
proﬁle and is not associated with severe complications as
clozapine,suchasagranulocytosis,seizures,myocarditis,and
pancreatitis [9–11]. Therefore, we consider quetiapine as a
ﬁrst-line treatment for a psychotic patient with a concurrent
prolactin-related disturbance, such as a prolactinoma.
An in vivo study has shown that quinagolide crosses the
blood-brain barrier to a lesser degree than bromocriptine
and should, hence, be expected to exert a marked eﬀect
on the pituitary but less inﬂuence on the brain and the
mental status [4]. Quinagolide is also a relatively selective
D2 agonist, whereas bromocriptine has a more unselective
receptor proﬁle. Thus, it seems probable that quinagolide
may be a more favorable dopamine agonist for patients
with prolactinoma and psychotic disorder [4]. Nevertheless,
bromocriptinewassuccessfullyusedandwelltoleratedinﬁve
of the reviewed cases [4, 5, 8].
The clinical management of the presented comorbid
aﬀections requires special attention. A closer followup,
especially in the beginning of the treatment, is mandatory,
at least until the balance between prolactin serum levels
and psychotic symptoms is achieved. The speciﬁc choice
of both dopaminergic agonist and antagonist medications
should be made individually. Selective dopaminergic agents,
such as quinagolide, and antipsychotics with less action
in the tuberoinfundibular pathway, such as quetiapine and
clozapine, are theoretically preferable drugs. Surgery and
radiotherapy are options for refractory cases.
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